Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kristen Schreiber

Physician Assistant Saint Louis, MO Physician Assistant

NPI 1447748967 CMS profile 10734327

12855 N 40 Dr Ste 375, Saint Louis, MO 63141

Open in the dashboard

General payments

$13,993

510 records reported · program years 2021–2025

Research payments

$490

Paid to them · 2 records reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kristen Schreiber of Saint Louis, MO is reported in the CMS Open Payments database as having received $13,993 across 510 general payments and $490 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,501 119
2024 General $2,788 97
2024 Research $490 2
2023 General $2,633 92
2022 General $2,182 117
2021 General $1,890 85

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kristen Schreiber
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Kristen Schreiber were reported at $4,501. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Kristen Schreiber Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,890 $132 $37–$438 $132
2022 $2,182 $155 $48–$522 $149
2023 $2,633 $167 $52–$557 $160
2024 $2,788 $178 $55–$600 $164
2025 $4,501 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boston Scientific Corporation $1,461 13 payments
  2. Janssen Biotech, Inc. $1,347 46 payments
  3. Dendreon Pharmaceuticals LLC $941 35 payments
  4. Medtronic, Inc. $933 12 payments
  5. Sumitomo Pharma America, Inc. $917 57 payments
  6. Ferring Pharmaceuticals Inc. $814 26 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $787 25 payments
  8. Antares Pharma, Inc. $648 56 payments
  9. ConvaTec Inc. $628 15 payments
  10. Teleflex LLC $599 9 payments
  11. Other $4,918 216 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,840 503 payments
  2. Travel and Lodging $778 2 payments
  3. Education $375 5 payments
Products named General payments · program years 2021–2025
  1. Axonics $1,285 10 payments
  2. ERLEADA $1,124 44 payments
  3. GEMTESA $1,087 72 payments
  4. PROVENGE $941 35 payments
  5. INTERSTIM $892 11 payments
  6. ADSTILADRIN $814 26 payments
  7. Nubeqa $655 24 payments
  8. GENTLECATH $628 15 payments
  9. XYOSTED $453 40 payments
  10. PROLARIS $451 11 payments
  11. Other $7,349 335 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2025
  1. Medtronic, Inc. $490 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

3,325

Median for Physician Assistant: 241

Drug cost

$1,154,128

Median for Physician Assistant: $4,110

Branded share of claims

57.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 733 $598,755
Myrbetriq Mirabegron Brand 619 $429,557
Mirabegron Er Mirabegron Brand 69 $33,865
Trospium Chloride Er Trospium Chloride Brand 148 $26,589
Methenamine Hippurate Generic 404 $25,324
Estradiol Generic 180 $11,576
Trospium Chloride Generic 194 $7,711
Premarin Estrogens, Conjugated Brand 14 $6,420
Solifenacin Succinate Generic 57 $2,971
Yuvafem Estradiol Brand 16 $1,905

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$117,630

Of which drugs: $1,015

Medicare patients

822

Average age 76

Services billed

5,973

766 women, 56 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 63%
Depression 32%
Osteoporosis 31%
Diabetes 20%
Ischemic heart disease 20%
Chronic kidney disease 20%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 25 2,035 $207

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ADSTILADRIN
  • Ferring Pharmaceuticals Inc. $294
$294 — —
BOTOX
  • AbbVie, Inc. $209
$209 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $206
$206 733 —
ERLEADA
  • Janssen Biotech, Inc. $198
$198 — —
PROVENGE
  • Dendreon Pharmaceuticals LLC $178
$178 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

512 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record